Epidemiology/Health Services Research

Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study

  1. Victor W. Zhong1,2,
  2. Juhaeri Juhaeri3 and
  3. Elizabeth J. Mayer-Davis1,4⇑
  1. 1Department of Nutrition, Gillings School of Global Public Health, University of North Carolina, Chapel Hill, NC
  2. 2Department of Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL
  3. 3Global Pharmacovigilance and Epidemiology, Sanofi US, Bridgewater, NJ
  4. 4Department of Medicine, School of Medicine, University of North Carolina, Chapel Hill, NC
  1. Corresponding author: Elizabeth J. Mayer-Davis, mayerdav{at}email.unc.edu.
Diabetes Care 2018 Sep; 41(9): 1870-1877. https://doi.org/10.2337/dc17-1583

Abstract

OBJECTIVE This study determined trends in hospital admission for diabetic ketoacidosis (DKA) in adults with type 1 diabetes mellitus (T1DM) and type 2 diabetes mellitus (T2DM) from 1998 to 2013 in England.

RESEARCH DESIGN AND METHODS The study population included 23,246 adults with T1DM and 241,441 adults with T2DM from the Clinical Practice Research Datalink (CPRD) and Hospital Episode Statistics (HES). All hospital admissions for DKA as the primary diagnosis from 1998 to 2013 were identified. Trends in hospital admission for DKA in incidence, length of hospital stay, 30-day all-cause readmission rate, and 30-day and 1-year all-cause mortality rates were determined using joinpoint regression, negative binomial regression, and logistic regression models.

RESULTS For T1DM, the incidence of hospital admission for DKA increased between 1998 and 2007 and remained static until 2013. The incidence in 2013 was higher than that in 1998 (incidence rate ratio 1.53 [95% CI 1.09–2.16]). For T2DM, the incidence increased 4.24% (2.82–5.69) annually between 1998 and 2013. The length of hospital stay decreased over time for both diabetes types (P ≤ 0.0004). Adults with T1DM were more likely to be discharged within 2 days compared with adults with T2DM (odds ratio [OR] 1.28 [1.07–1.53]). The 30-day readmission rate was higher in T1DM than in T2DM (OR 1.61 [1.04–2.50]) but remained unchanged for both diabetes types over time. Trends in 30-day and 1-year all-cause mortality rates were also stable, with no difference by diabetes type.

CONCLUSIONS In the previous two decades in England, hospitalization for DKA increased in adults with T1DM and in those with T2DM, and associated health care performance did not improve except decreased length of hospital stay.

Introduction

Hospital admission for diabetic ketoacidosis (DKA) is a potentially life-threatening but largely preventable complication in diabetes (1–3) and is associated with significant health care utilization and expenditure (4,5). Previous studies focused on describing DKA trends in children (6–9); however, >80% of patients with DKA are adults (1), among whom data for long-term trends are limited. The available studies in adults from different countries reported increased (10,11), stable (12), or slightly declined (13) rates of DKA admission to the hospital, emergency department, or intensive care unit. Other studies in adults found declined hospitalization rates for hyperglycemia as a whole (14,15). However, none of these studies assessed DKA trends by diabetes type. Type 2 diabetes mellitus (T2DM) is the predominant diabetes type in adults, whereas DKA risk is substantially higher in type 1 diabetes mellitus (T1DM) than in T2DM (1). Thus, direct application of DKA trends identified from all people with diabetes to each specific diabetes type is misleading. Using primary care data from the Clinical Practice Research Datalink (CPRD) and linked secondary care data from the Hospital Episode Statistics (HES), we aimed to determine DKA trends in incidence, length of hospital stay, 30-day all-cause readmission rate, and 30-day and 1-year all-cause mortality rates, from 1998 to 2013, in adults with T1DM or T2DM in England, respectively.

Research Design and Methods

Data Source

The CPRD, one of the largest electronic medical record databases in the world, collects anonymous longitudinal patient records from 684 general practices from England, Scotland, Wales, and Northern Ireland as of January 2015. Patients within the CPRD are broadly representative of the population in the U.K. in age, sex, and ethnicity (16). The CPRD contains rich primary care information including, but not limited to, basic demographics, prescribed medications, clinical diagnoses, and laboratory test results. The CPRD is linked to a secondary care database via a trusted third party, the HES, which houses patient-level information on all hospital admissions to National Health Service hospitals in England. The study population was from 398 of the 684 CPRD practices that agreed to be linked to the HES between 1 April 1997 and 31 March 2014. The linked CPRD-HES population is representative of the entire CPRD population (17). Hospital admissions for DKA were identified from the HES, and all other data were extracted from the CPRD. The study protocol (No. 15_259RA) was approved by the Independent Scientific Advisory Committee for Medicines & Healthcare Products Regulatory Agency in London, U.K. A minor modification was made to the approved protocol, which did not need an amendment submission. We included two additional variables, length of hospital stay and mortality, that measure quality of care (18,19).

T1DM and T2DM Definition

The definition for T1DM and T2DM was previously published (20). Specifically, among individuals with one or more diabetes-related diagnosis code, we defined T1DM as having any one of the following criteria: 1) one or more T1DM codes and insulin use only; 2) one or more T1DM codes and insulin use only on the diagnosis date and noninsulin glucose-lowering drug (NIGLD), if any, was introduced 6 months later; 3) two or more insulin prescriptions only. T2DM was defined as having any one of the following criteria: 1) two or more T2DM codes and no T1DM code, regardless of drug use; 2) one or more T2DM codes and no T1DM code and NIGLD use only; 3) one or more T2DM codes and no T1DM code and being treated with both NIGLD and insulin, but NIGLD prescribed no later than insulin; 4) two or more classes of NIGLD; 5) two or more prescriptions of a noninsulin nonmetformin glucose-lowering drug only. NIGLDs included metformin, sulfonylureas, glinide, thiazolidinediones, inhibitors of dipeptidyl peptidase 4, inhibitors of sodium-glucose cotransporter 2, glucagon-like peptide 1 receptor agonists, and acarbose. Patients were excluded if they had nonresearch quality data determined by the CPRD team based on the prespecified data quality metrics or had a record of secondary diabetes, maturity onset diabetes of young, latent autoimmune diabetes in adults, or malnutrition-related diabetes.

Patient Follow-up and DKA Diagnosis

The full-year HES data were available between 1998 and 2013. The follow-up started at the latest of the following dates: 1 January 1998, first diabetes visit, patient registration, up to standard date (16), or 18 years old. Follow-up ended at the earliest of the following dates: 31 December 2013, death, transfer out, or last data collection for the practice. DKA (E10.1, E11.1, E12.1, E13.1, and E14.1) listed as primary diagnosis for hospital admission during follow-up was identified. We included all DKA admissions for analyses. Because DKA could be the first presentation of diabetes (1,21), we also included DKA admissions with hospital admission date within 28 days before the first diabetes visit date documented in the CPRD.

Statistical Analysis

All analyses were performed separately by diabetes type. The incidence rate of hospital admission for DKA was calculated by dividing the total number of DKA admissions by the total accumulated person-years with diabetes within each year between 1998 and 2013. We computed the age standardized incidence rate using the entire study sample as the reference population, according to these age categories in T1DM (18–24, 25–34, 35–49, ≥50 years) and T2DM (18–49, 50–64, ≥65 years). For T1DM, age standardized incidence rates were also given by sex (male, female), duration of recorded diabetes history (as an alternative for diabetes duration; <1, 1–9, 10–19, and ≥20 years), Charlson comorbidity score (1, 2, 3, and ≥4) (22), and region (North East, North West, Yorkshire and The Humber, East Midlands, West Midlands, East of England, South West, South Central, London, and South East Coast). For T2DM, age standardized incidence rates were given by sex, duration of recorded diabetes history (<1, 1–4, 5–9, and ≥10 years), Charlson comorbidity score (1, 2, 3, and ≥4), current use of glucose-lowering drugs (sulfonylureas with or without NIGLD, insulin only, insulin and NIGLD, and other), and region.

Trends in the incidence for hospital admission for DKA were estimated using joinpoint regression models (23). Annual percentage change and 95% CI were quantified. Length of hospital stay in days was calculated for adults with T1DM or T2DM and was then categorized into four categories (0–2 days, 3–6 days, ≥1 but <2 weeks, and ≥2 weeks). Also calculated were the 30-day all-cause readmission rate and 30-day and 1-year all-cause mortality rates. Trends in the length of hospital stay were determined by negative binomial regression models. Trends in the four categories of hospital stay were estimated using ordinal logistic regression models. Trends in the 30-day all-cause readmission rate and 30-day and 1-year all-cause mortality rates were examined using logistic regression models. All models included calendar year, age, sex, duration of recorded diabetes history, Charlson comorbidity score, and current use of glucose-lowering drugs (for T2DM only). Nonlinearity was assessed by adding a quadratic term for year. Differences between T1DM and T2DM (reference group) were also compared. Incidence rate ratios (IRRs) or odds ratios (ORs) and 95% CIs were presented. To account for DKA as a recurrent event, we applied robust error estimate for correlated data in all models implemented by using the PROC GENMOD procedure with the REPEATED statement (24,25) in SAS 9.4 software (SAS Institute). Statistical significance was indicated by a two-sided P value <0.05.

Sensitivity analyses were conducted to evaluate the effect of potential misclassification of diabetes type on DKA trends. Previous investigation revealed that the aforementioned criteria 2 and 3 for T1DM and criterion 3 for T2DM were mostly likely to misclassify diabetes type from clinical perspectives (20). A decent proportion of adults with T1DM (11.86%) and a small proportion of adults with T2DM (0.33%) may have been incorrectly classified. We reestimated DKA trends by removing these patients. We also evaluated whether DKA trends were materially influenced by any single year data.

Our primary goal was to estimate the burden of hospital admission for DKA over time in England, and thus, our primary analyses focused on all available DKA hospital admissions from each included patient. Secondary analyses were conducted to determine whether the observed DKA trends were driven by a group of patients who had multiple DKA hospital admissions. We reassessed the trends by 1) analyzing only the first DKA hospital admission from each patient during the entire study period and 2) analyzing only the first DKA hospital admission in each year from each patient. Characteristics of patients were also described according to the number of DKA hospital admissions during the entire study period (none, one, two, three or more for T1DM and none, one, and two or more for T2DM). Further, the length of hospital stay and 30-day and 1-year all-cause mortality were compared between patients with different numbers of DKA hospital admissions (one vs. two or three or more for T1DM and one vs. two or more for T2DM), using the aforementioned modeling approaches. In addition, among patients with at least one DKA hospital admission, we assessed the 30-day all-cause readmission rate by including only the first 30-day hospital readmission for DKA during the entire study period for each patient or the first 30-day readmission in each year for each patient.

Results

Among 23,246 adults with T1DM, 4,346 hospital admissions for DKA were identified during 121,258 person-years of follow-up (Supplementary Table 1). The incidence of hospital admission for DKA was 35.84 per 1,000 person-years during the entire study period. Among 241,441 adults with T2DM, 1,148 DKA hospital admissions were found during 1,342,896 person-years of follow-up, with an incidence of 0.85 per 1,000 person-years (Supplementary Table 2). Every one in five DKA hospital admissions was attributed to T2DM. The mean (SD) of age was 46.66 (17.67) years in T1DM and 66.41 (13.19) years in T2DM.

In adults with T1DM, the incidence for hospital admission for DKA did not have any significant change between 1998 and 2004 and then substantially increased by 14.10% (95% CI 2.34–27.22, P = 0.02) annually from 2004 to 2007 (Fig. 1A). The incidence then remained largely stable. The incidence was much higher in 2013 than in 1998 (IRR 1.53 [1.09–2.16]). Trends in DKA hospital admission increased during the entire study period among adults with T1DM aged ≥35 years (Supplementary Fig. 1A and Supplementary Table 3), who were male (Supplementary Fig. 1B), with <1 year or ≥20 years of recorded diabetes history (Supplementary Fig. 1C), and few comorbidities (Supplementary Fig. 1D). A nonlinear trend was only seen in the South West region (Supplementary Fig. 1E). The incidence of hospital admission for DKA was the highest among adults with T1DM with <1 year of recorded diabetes history and young adults aged 18–24 years.

Figure 1
Figure 1

Trends in hospital admission for DKA in adults with T1DM (A) or T2DM (B). Black dots represent age standardized incidence rate in each year. Solid line represent estimated trend from using joinpoint regression. APC and 95% CI, along with P value for trend, are shown. The standard population for calculating age standardized incidence was the entire cohort of adults with T1DM or T2DM during the study period. The following age categories were used: 18–24, 25–34, 35–49, and ≥50 years for T1DM, and 18–49, 50–64, and ≥65 years for T2DM. APC, annual percent change.

In adults with T2DM, the incidence of hospital admission for DKA increased from 0.70 to 0.98 per 1,000 person-years (Supplementary Table 2). The annual increase was 4.24% (95% CI 2.82–5.69, P < 0.0001) (Fig. 1B). The incidence increased among those aged <50 or ≥65 (Supplementary Fig. 2A and Supplementary Table 3), for both sexes (Supplementary Fig. 2B), with ≥10 years of recorded diabetes history (Supplementary Fig. 2C), and current insulin users (Supplementary Fig. 2E). The trend was stable among sulfonylureas users. A decreasing trend was observed among adults with T2DM who were not currently being treated with insulin and sulfonylureas. No nonlinear trend was found by region (Supplementary Fig. 2F). Of note, the incidence of hospital admission for DKA was the highest among insulin users and also high in young adults and those with <1 year or ≥10 years of recorded diabetes history.

The median length of hospital stay in days decreased over time for both T1DM (P < 0.0001) and T2DM (P = 0.0004) (Fig. 2A). No difference was found between two diabetes types (rate ratio 0.93 [95% CI 0.81–1.07]). When hospital stay was examined as a categorical variable (Fig. 2B and C), adults with T1DM were more likely to be discharged within 2 days (OR 1.28 [1.07–1.53]) compared with adults with T2DM.

Figure 2
Figure 2

Trends in median length of hospital stay (A) and by categories in adults with T1DM (B) or T2DM (C). Estimates were obtained from negative binomial models for A and from ordinal logistic regression models for B and C, with robust error variance to account for recurrent DKA admissions. Estimates were adjusted for calendar year, age, sex, duration of record diabetes history, Charlson comorbidity score, and current use of glucose-lowering drugs (for T2DM only). Adults with T1DM were more likely to be discharged within 2 days (OR 1.28 [95% CI 1.07–1.53]) compared with adults with T2DM.

The 30-day all-cause readmission rate did not change over time for T1DM (P = 0.94) and T2DM (P = 0.13), but the readmission rate was higher in T1DM than in T2DM (OR 1.61 [95% CI 1.04–2.50]) (Fig. 3). Similarly, 30-day and 1-year all-cause mortality rates both remained unchanged for both diabetes types (P > 0.3) (Fig. 4A and B). The mortality rate did not differ by diabetes type.

Figure 3
Figure 3

Trends in 30-day all-cause readmission rate for hospital admission for DKA. Estimates were obtained from logistic regression models with robust error variance to account for recurrent DKA admissions. Estimates were adjusted for calendar year, age, sex, duration of recorded diabetes history, Charlson comorbidity score, and current use of glucose-lowering drugs (for T2DM only).

Figure 4
Figure 4

Trends in the 30-day (A) and 1-year (B) all-cause mortality rate. Estimates were obtained from logistic regression models with robust error variance to account for recurrent DKA admissions. Estimates were adjusted for calendar year, age, sex, duration of recorded diabetes history, Charlson comorbidity score, and current use of glucose-lowering drugs (for T2DM only).

Sensitivity analyses revealed that after excluding likely-to-be-misclassified adults with T1DM, the incidence of hospital admission for DKA increased 7.41% (95% CI 5.23–9.65, P < 0.0001) annually between 1998 and 2009, and no significant change was observed after then. After excluding likely-to-be-misclassified adults with T2DM, the incidence increased 4.35% (2.80–5.92, P < 0.0001) annually between 1998 and 2013. For T1DM using the entire sample, if we excluded the year 2004 data, an annual increase of 5.21% (2.67–6.77, P < 0.0001) was seen between 1998 and 2009, and then the incidence remained unchanged (Supplementary Fig. 3).

At least two hospital admissions for DKA occurred in 3.17–4.42% of adults with T1DM and 0.05–0.13% of adults with T2DM in three selected years (Supplementary Table 4). Compared with those without DKA hospital admission or with only one admission, adults with T1DM who had recurrent DKA admissions were younger (P < 0.0001), and adults with T2DM who had recurrent DKA admissions were younger, less likely to be male, had longer duration of recorded diabetes history, and were more likely to be receiving insulin therapy (P < 0.0001). The number of patients included in each year and according to the number of hospital admission for DKA were also shown for T1DM (Supplementary Table 5) and T2DM (Supplementary Table 6). Further analysis revealed that 65.72% and 35.28% of the total DKA hospital admissions were recurrent for T1DM and T2DM, respectively.

For T1DM, the incidence of hospital admission for DKA in 2013 was 21.44, 29.40, and 39.13 per 1,000 person-years, respectively, when including only the first DKA admission during the entire study period (Supplementary Fig. 4A), the first DKA admission in each year (Supplementary Fig. 5A), and all DKA admissions (Fig. 1A) from each patient. The DKA trends increased 1.63% (95% CI 0.32–2.95, P = 0.02) and 3.10% (1.93–4.28, P = 0.0001) annually between 1998 and 2013, respectively, when analyzing only the first DKA admission during the entire study period and the first DKA admission in each year. For T2DM, the incidence of hospital admission for DKA in 2013 was 0.68, 0.84, and 0.98 per 1,000 person-years, respectively, when including only the first DKA admission during the entire study period (Supplementary Fig. 4B), the first DKA admission in each year (Supplementary Fig. 5B), and all DKA admissions (Fig. 1B) from each patient. The DKA trends increased 2.02% (0.27–3.81, P = 0.03) and 3.40% (1.82–5.00, P = 0.0004) annually between 1998 and 2013, respectively, when analyzing only the first DKA admission during the entire study period and the first DKA admission in each year.

During the entire study period, the average 30-day all-cause readmission rate decreased from 12.67 to 6.05% for T1DM and from 6.18 to 3.74% for T2DM when comparing the analysis with including all DKA hospital admissions to including only the first DKA readmission for each patient (Supplementary Table 7). Similar to the primary analysis with all DKA admissions included (Fig. 3), the trends in the 30-day all-cause readmission rate remained stable over time for both T1DM and T2DM (P > 0.1) (Supplementary Fig. 6A and B). Adults with T1DM with three or more DKA admissions (OR 1.90 [95% CI 1.15–3.13]) and adults with T2DM with two or more DKA admissions (2.05 [1.16–3.62]) were associated with higher 1-year all-cause mortality compared with those adults with T1DM or T2DM with only one DKA admission (Supplementary Table 8). No difference was found for 30-day all-cause mortality and length of hospital stay for both T1DM and T2DM.

Conclusions

Among a large representative cohort of adults with T1DM or T2DM in England, from 1998 to 2013, we found an increased incidence of hospital admission for DKA before 2007 and no change was seen after then for adults with T1DM. The incidence of hospital admission for DKA increased steadily among adults with T2DM during the entire period. About 20% of all DKA admissions were from adults with T2DM. The length of hospital stay for adults with T1DM or T2DM decreased over time, but the 30-day all-cause readmission rate and 30-day and 1-year all-cause mortality rates remained unchanged. Nonetheless, adults with T1DM were more likely to be discharged within 2 days and also had higher readmission rate than adults with T2DM. These findings provide informative data to understand the long-term DKA burden and associated health care performance in England and to inform future practice-level or policy-level intervention for reducing DKA burden.

DKA is a well-recognized hallmark of T1DM, but our findings suggest that managing DKA in adults with T1DM has not been successful in England. We found that the incidence of hospital admission for DKA was 53% higher in 2013 than in 1998, although the incidence stopped increasing after 2007. Given the substantially higher DKA risk in T1DM than in T2DM, an elevated DKA trend in T1DM would contribute considerable health care and patient burden. Importantly, the increasing trend was the most prominent among adults with T1DM with <1 year of recorded diabetes history who also had the highest risk for DKA hospitalization. This subgroup of patients requires particular attention. For T2DM, most of the DKA admissions were from insulin users, and the increase in DKA incidence among insulin users was also the greatest among all subgroups of adults with T2DM, suggesting that appropriate use of and adherence to insulin therapy have been challenging.

Our data suggest that the incidence of hospital admission for DKA was >40-fold higher in T1DM than in T2DM, but every one in five DKA admissions was attributed to T2DM. These concur with the evidence from Wales, U.K. (11), the U.S. (26), and Nordic countries (27,28). The contribution of DKA burden from T2DM is more significant than traditionally recognized when DKA was considered a key clinical feature for T1DM (2). In fact, we revealed a steady increase in the incidence of hospital admission for DKA in T2DM. The underlying causes are unclear, but rising T2DM prevalence and incidence may be one (29). The risk of hospital admission for DKA was higher among those with <1 year or ≥10 years of recorded diabetes history. In our study population, the proportion of adults with T2DM with <1 year of recorded diabetes history decreased over time (Supplementary Fig. 7), but more adults had ≥10 years of recorded diabetes history. Therefore, the aging of population with T2DM may play a more important role. Although speculative, other reasons may be increased insulin use and increased prevalence of infection and ketosis-prone T2DM over time. Infection and noncompliance to insulin therapy are two of the most common precipitating factors for DKA (3). Whether there is an increased trend of infection in T2DM patients paralleling increased DKA trends needs future investigation. Our data indicate that insulin users had the greatest risk for DKA hospital admission in T2DM. A previous study reported that the prevalence of insulin use increased in earlier years before 2005 and then remained in that high level (20). DKA is commonly seen in ketosis-prone T2DM, which usually occurs in nonwhite patients (2), but correctly phenotyping this subtype is difficult.

Length of hospital stay and 30-day all-cause readmission and mortality rates are commonly used outcome measures for health care utilization and performance (18,19). The declining trend in DKA-related length of hospital stay found in our study may imply reduced hospital costs per DKA admission and improved treatment and management. Discrepancy existed by diabetes type. Adults with T1DM were much more likely to be discharged within 2 days (65% vs. 29% in 2013), which may be partly related to adults with T2DM being ∼20 years older than adults with T1DM. Although speculative, the shortened hospital stay may partly account for the unchanged 30-day all-cause readmission rate and 30-day and 1-year all-cause mortality rates, because it may be likely that patients were discharged too quickly before they were fully treated to reduce health care costs. However, the temporal relationship between length of hospital stay, short-term readmission and mortality rates, and hospital costs requires more investigations.

Approximately two-thirds of all DKA hospital admissions in T1DM and one-third in T2DM (mostly insulin users) were recurrent cases in our study. Therefore, restricting analyses to include only the first DKA hospital admission and the first DKA readmission considerably reduced the incidence rate and 30-day readmission rate for DKA, respectively. Nonetheless, we still observed an elevation of trends in hospital admission for DKA for both T1DM and T2DM during the entire study period after applying these restrictions. Other than previously hypothesized reasons for the rising DKA trends, the diagnostic criteria of DKA from the American Diabetes Association in 2001 recommended a classification of the severity of DKA (mild, moderate, and severe) to help with patient disposition and selection of therapy (30). The specific inclusion of DKA with mild metabolic acidosis may have resulted in an increased number of DKA cases, although patients with mild DKA can be treated and observed in the emergency department and may not be admitted for hospitalization.

Reducing DKA risk in adults has been challenging. Possibly, managing chronic complications, such as retinopathy, nephropathy, neuropathy, and amputation and cardiovascular disease risk, are the priorities, and cardiovascular disease is the primary cause of death and source of health care costs in people with T1DM or T2DM (31–33). However, managing acute complications such as DKA deserves more attention. Our study and most of the published studies across different countries reported increased/stable DKA rates or an increased number of hospital admissions, or both (10–12). Ideal management for DKA should prevent both the first and recurrent DKA and improve care during hospitalization and immediately after discharge. Unlike hypoglycemia, which is totally preventable (34), some DKA cases may not have an obvious precipitating cause, particularly in ketosis-prone patients with T2DM (1–3). Nonetheless, most DKA cases are preventable through implementing structured educational programs emphasizing the importance of continuation of and adherence to insulin therapy, improving sick day management (e.g., increase insulin doses if unwell, test ketones), having medications available for treating fever or infection, accessing medical care easily, and enhancing communication with a health care provider during an intercurrent illness (1–3).

Our study had several important limitations. First, we did not have data on DKA events admitted to the emergency department but not resulting in hospitalization. Second, misclassification of diabetes type was likely. Sensitivity analyses suggested that the potential misclassification would not change our conclusions. However, we could not rule out the possibility of misdiagnosing ketosis-prone T2DM as T1DM, and thus, its effect on the DKA trends in T1DM and T2DM was unknown (2,35). Third, the identification of DKA admissions was solely based on the ICD-10 diagnosis code and was not verified by laboratory criteria such as glucose level, pH level, serum bicarbonate level, anion gap, and serum/urine ketones level. Accordingly, DKA could have been miscoded or misdiagnosed. Fourth, the introduction of the Quality and Outcomes Framework (QOF) in 2004 may improve data completeness and facilitate identification of patients with diabetes in the CPRD (36). Coincidentally, the greatest increase was observed between 2004 and 2007 for adults with T1DM, although the incidence of hospital admission for DKA already went up before 2003. Our sensitivity analyses indicated that the trend before 2007 was largely influenced by the year 2004 data; dropping this year yielded a significant increase between 1998 and 2007. Also, we did not observe any unusual trends in 2004–2007 in the following variables in T1DM adults, including the number of included adults with T1DM, the number of DKA admissions, person-years with diabetes, percentage of adults with T1DM with duration of recorded diabetes history <1 year, percentage male, and percentage of patients aged 18–24 (Supplementary Table 9). Taken together, it is unlikely that our conclusion regarding the trends in hospital admission for DKA in T1DM adults was biased. Fifth, extending current DKA trends beyond 2013 should be done cautiously. Several changes were made in December 2015 and May 2017 to update the 2009 diabetes guideline from the National Institute for Health and Care Excellence in the U.K. (37,38). For example, sodium-glucose cotransporter 2 inhibitors have been added to the glucose-lowering therapy algorithm, and the recommended HbA1c target level is 6.5% (48 mmol/mol) and 7.0% (53 mmol/mol) if more than one glucose-lowering drug is prescribed. It remains unknown whether these changes have influenced the DKA trends beyond 2013, although we do not anticipate any dramatic alteration in the DKA trends between 2014 and the time of the publication of this study. Sixth, DKA trends from our study may not be applicable to health care systems beyond the U.K. Seventh, we did not correct for multiple comparisons, and thus, we could not rule out that some findings may be due to chance. Lastly, we underestimated duration of diabetes, because we used the first diabetes visit date as an approximate for the diabetes diagnosis date. To avoid confusion, we used duration of recorded diabetes history throughout instead of diabetes duration.

In summary, reducing DKA hospital admission is urgent for adults with T1DM or T2DM in England, given the high incidence of hospital admission for DKA in T1DM and the increasing trend in T2DM. Adults with T2DM contribute 20% of DKA admissions, although the admission rate is 40-fold higher in adults with T1DM. In addition to preventing DKA hospital admission, successful management also needs to reduce short-term all-cause readmission and mortality rates for which stable trends have been seen in England. Future investigations are required to identify factors that contribute to the increased DKA risk and unchanged readmission and mortality rates for DKA.

Article Information

Acknowledgments. The authors sincerely thank Meera Kumar and Ling Zhang, from Sanofi US (Bridgewater, NJ), for extracting the CPRD and HES data.

Funding. This study was supported by the Sanofi Global Nutrition Scholars program at the University of North Carolina at Chapel Hill.

Duality of Interest. V.W.Z. received financial support from the Sanofi Global Nutrition Scholars program, and J.J. is an employee of Sanofi US, Bridgewater, NJ. No other potential conflicts of interest relevant to this article were reported.

Author Contributions. V.W.Z. analyzed the data and wrote and revised the manuscript. V.W.Z. and J.J. acquired the data. V.W.Z. and E.J.M.-D. designed the study. All authors reviewed and edited the manuscript and contributed to discussion. V.W.Z. and E.J.M.-D. are the guarantors of this work and, as such, had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis.

Footnotes

  • Received July 31, 2017.
  • Accepted December 30, 2017.
http://www.diabetesjournals.org/content/license

Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.

References

  1. ↵
    1. Kitabchi AE,
    2. Umpierrez GE,
    3. Miles JM,
    4. Fisher JN
    . Hyperglycemic crises in adult patients with diabetes. Diabetes Care 2009;32:1335–1343pmid:19564476
    OpenUrlFREE Full Text
  2. ↵
    1. Misra S,
    2. Oliver N,
    3. Dornhorst A
    . Diabetic ketoacidosis: not always due to type 1 diabetes. BMJ 2013;346:f3501pmid:23751904
    OpenUrlFREE Full Text
  3. ↵
    1. Misra S,
    2. Oliver NS
    . Diabetic ketoacidosis in adults. BMJ 2015;351:h5660pmid:26510442
    OpenUrlFREE Full Text
  4. ↵
    1. Hex N,
    2. Bartlett C,
    3. Wright D,
    4. Taylor M,
    5. Varley D
    . Estimating the current and future costs of type 1 and type 2 diabetes in the UK, including direct health costs and indirect societal and productivity costs. Diabet Med 2012;29:855–862pmid:22537247
    OpenUrlCrossRefPubMed
  5. ↵
    1. Dhatariya KK,
    2. Skedgel C,
    3. Fordham R
    . The cost of treating diabetic ketoacidosis in the UK: a national survey of hospital resource use. Diabet Med 2017;34:1361–1366pmid:28727175
    OpenUrlPubMed
  6. ↵
    1. Dabelea D,
    2. Rewers A,
    3. Stafford JM, et al.; SEARCH for Diabetes in Youth Study Group
    . Trends in the prevalence of ketoacidosis at diabetes diagnosis: the SEARCH for Diabetes in Youth Study. Pediatrics 2014;133:e938–e945pmid:24685959
    OpenUrlAbstract/FREE Full Text
    1. Hekkala A,
    2. Knip M,
    3. Veijola R
    . Ketoacidosis at diagnosis of type 1 diabetes in children in northern Finland: temporal changes over 20 years. Diabetes Care 2007;30:861–866pmid:17392547
    OpenUrlAbstract/FREE Full Text
    1. Fritsch M,
    2. Schober E,
    3. Rami-Merhar B,
    4. Hofer S,
    5. Fröhlich-Reiterer E,
    6. Waldhoer T; Austrian Diabetes Incidence Study Group
    . Diabetic ketoacidosis at diagnosis in Austrian children: a population-based analysis, 1989-2011. J Pediatr 2013;163:1484–1488.e1pmid:23953724
    OpenUrlPubMed
  9. ↵
    1. Neu A,
    2. Hofer SE,
    3. Karges B,
    4. Oeverink R,
    5. Rosenbauer J,
    6. Holl RW; DPV Initiative and the German BMBF Competency Network for Diabetes Mellitus
    . Ketoacidosis at diabetes onset is still frequent in children and adolescents: a multicenter analysis of 14,664 patients from 106 institutions. Diabetes Care 2009;32:1647–1648pmid:19549730
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Ko SH,
    2. Lee WY,
    3. Lee JH, et al
    . Clinical characteristics of diabetic ketoacidosis in Korea over the past two decades. Diabet Med 2005;22:466–469pmid:15787674
    OpenUrlPubMed
  11. ↵
    1. Abdulrahman GO,
    2. Amphlett B,
    3. Okosieme OE
    . Trends in hospital admissions with diabetic ketoacidosis in Wales, 1999-2010. Diabetes Res Clin Pract 2013;100:e7–e10pmid:23380135
    OpenUrlPubMed
  12. ↵
    1. Ginde AA,
    2. Pelletier AJ,
    3. Camargo CA Jr
    . National study of U.S. emergency department visits with diabetic ketoacidosis, 1993-2003. Diabetes Care 2006;29:2117–2119pmid:16936163
    OpenUrlFREE Full Text
  13. ↵
    1. Liu CC,
    2. Chen KR,
    3. Chen HF,
    4. Huang HL,
    5. Ko MC,
    6. Li CY
    . Trends in hospitalization for diabetic ketoacidosis in diabetic patients in Taiwan: analysis of national claims data, 1997-2005. J Formos Med Assoc 2010;109:725–734pmid:20970069
    OpenUrlPubMed
  14. ↵
    1. Lombardo F,
    2. Maggini M,
    3. Gruden G,
    4. Bruno G
    . Temporal trend in hospitalizations for acute diabetic complications: a nationwide study, Italy, 2001-2010. PLoS One 2013;8:e63675pmid:23717464
    OpenUrlCrossRefPubMed
  15. ↵
    1. Lipska KJ,
    2. Ross JS,
    3. Wang Y, et al
    . National trends in US hospital admissions for hyperglycemia and hypoglycemia among Medicare beneficiaries, 1999 to 2011. JAMA Intern Med 2014;174:1116–1124pmid:24838229
    OpenUrlCrossRefPubMed
  16. ↵
    1. Herrett E,
    2. Gallagher AM,
    3. Bhaskaran K, et al
    . Data resource profile: Clinical Practice Research Datalink (CPRD). Int J Epidemiol 2015;44:827–836pmid:26050254
    OpenUrlCrossRefPubMed
  17. ↵
    1. Gallagher AM.
    2. Puri S,
    3. van Staa TP
    . Linkage of the General Practice Research Database (GPRD) with other data sources. Pharmacoepidemiol Drug Saf 2011;20:S230–S231
    OpenUrl
  18. ↵
    1. Krumholz HM,
    2. Keenan PS,
    3. Brush JE Jr, et al.; American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research; American College of Cardiology Foundation
    . Standards for measures used for public reporting of efficiency in health care: a scientific statement from the American Heart Association Interdisciplinary Council on Quality of Care and Outcomes Research and the American College of Cardiology Foundation. J Am Coll Cardiol 2008;52:1518–1526pmid:19017522
    OpenUrlFREE Full Text
  19. ↵
    1. Bueno H,
    2. Ross JS,
    3. Wang Y, et al
    . Trends in length of stay and short-term outcomes among Medicare patients hospitalized for heart failure, 1993-2006. JAMA 2010;303:2141–2147pmid:20516414
    OpenUrlCrossRefPubMedWeb of Science
  20. ↵
    1. Zhong VW,
    2. Juhaeri J,
    3. Cole SR, et al
    . Incidence and trends in hypoglycemia hospitalization in adults with type 1 and type 2 diabetes in England, 1998-2013: a retrospective cohort study. Diabetes Care 2017;40:1651–1660pmid:28716781
    OpenUrlAbstract/FREE Full Text
  21. ↵
    1. Hardern RD,
    2. Quinn ND
    . Emergency management of diabetic ketoacidosis in adults. Emerg Med J 2003;20:210–213pmid:12748130
    OpenUrlAbstract/FREE Full Text
  22. ↵
    1. Khan NF,
    2. Perera R,
    3. Harper S,
    4. Rose PW
    . Adaptation and validation of the Charlson Index for Read/OXMIS coded databases. BMC Fam Pract 2010;11:1
    OpenUrlCrossRefPubMed
  23. ↵
    National Cancer Institute, Division of Cancer Control and Population Sciences. Joinpoint Trend Analysis Software. Regression program, version 4.5.0.1 - June 2017. Available from https://surveillance.cancer.gov/joinpoint/. Accessed 7 November 2017
  24. ↵
    SAS Institute. Generalized estimating equations. SAS/STAT(R) 9.2 user's guide, second edition. Available from https://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm#statug_genmod_sect001.htm. Accessed 7 November 2017
  25. ↵
    1. Zou G
    . A modified Poisson regression approach to prospective studies with binary data. Am J Epidemiol 2004;159:702–706pmid:15033648
    OpenUrlCrossRefPubMedWeb of Science
  26. ↵
    1. Newton CA,
    2. Raskin P
    . Diabetic ketoacidosis in type 1 and type 2 diabetes mellitus: clinical and biochemical differences. Arch Intern Med 2004;164:1925–1931pmid:15451769
    OpenUrlCrossRefPubMedWeb of Science
  27. ↵
    1. Wang ZH,
    2. Kihl-Selstam E,
    3. Eriksson JW
    . Ketoacidosis occurs in both type 1 and type 2 diabetes--a population-based study from Northern Sweden. Diabet Med 2008;25:867–870pmid:18644074
    OpenUrlCrossRefPubMedWeb of Science
  28. ↵
    1. Henriksen OM,
    2. Røder ME,
    3. Prahl JB,
    4. Svendsen OL
    . Diabetic ketoacidosis in Denmark: incidence and mortality estimated from public health registries. Diabetes Res Clin Pract 2007;76:51–56pmid:16959363
    OpenUrlCrossRefPubMedWeb of Science
  29. ↵
    1. Sharma M,
    2. Nazareth I,
    3. Petersen I
    . Trends in incidence, prevalence and prescribing in type 2 diabetes mellitus between 2000 and 2013 in primary care: a retrospective cohort study [published correction appears in BMJ Open 2016;6:e010210corr1]. BMJ Open 2016;6:e010210
    OpenUrlAbstract/FREE Full Text
  30. ↵
    1. Kitabchi AE,
    2. Umpierrez GE,
    3. Murphy MB, et al
    . Management of hyperglycemic crises in patients with diabetes. Diabetes Care 2001;24:131–153pmid:11194218
    OpenUrlFREE Full Text
  31. ↵
    1. Laing SP,
    2. Swerdlow AJ,
    3. Slater SD, et al
    . Mortality from heart disease in a cohort of 23,000 patients with insulin-treated diabetes. Diabetologia 2003;46:760–765pmid:12774166
    OpenUrlCrossRefPubMedWeb of Science
    1. Paterson AD,
    2. Rutledge BN,
    3. Cleary PA,
    4. Lachin JM,
    5. Crow RS; Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group
    . The effect of intensive diabetes treatment on resting heart rate in type 1 diabetes: the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications study. Diabetes Care 2007;30:2107–2112pmid:17468351
    OpenUrlAbstract/FREE Full Text
  33. ↵
    1. Hogan P,
    2. Dall T,
    3. Nikolov P; American Diabetes Association
    . Economic costs of diabetes in the US in 2002. Diabetes Care 2003;26:917–932pmid:12610059
    OpenUrlAbstract/FREE Full Text
  34. ↵
    1. Seaquist ER,
    2. Anderson J,
    3. Childs B, et al
    . Hypoglycemia and diabetes: a report of a workgroup of the American Diabetes Association and the Endocrine Society. Diabetes Care 2013;36:1384–1395pmid:23589542
    OpenUrlAbstract/FREE Full Text
  35. ↵
    1. Xie XJ,
    2. Hu Y,
    3. Cheng C,
    4. Feng TT,
    5. He K,
    6. Mao XM
    . Should diabetic ketosis without acidosis be included in ketosis-prone type 2 diabetes mellitus? Diabetes Metab Res Rev 2014;30:54–59pmid:24038858
    OpenUrlPubMed
  36. ↵
    1. Kontopantelis E,
    2. Reeves D,
    3. Valderas JM,
    4. Campbell S,
    5. Doran T
    . Recorded quality of primary care for patients with diabetes in England before and after the introduction of a financial incentive scheme: a longitudinal observational study. BMJ Qual Saf 2013;22:53–64pmid:22918988
    OpenUrlAbstract/FREE Full Text
  37. ↵
    National Institute for Health and Care Excellence. Type 2 diabetes in adults: management. NG28. December 2015 (updated May 2017). Available from https://www.nice.org.uk/guidance/ng28. Accessed 24 December 2017
  38. ↵
    1. McGuire H,
    2. Longson D,
    3. Adler A,
    4. Farmer A,
    5. Lewin I; Guideline Development Group
    . Management of type 2 diabetes in adults: summary of updated NICE guidance. BMJ 2016;353:i1575pmid:27052837
    OpenUrlFREE Full Text
Back to top
View Selected Citations (0)
Print
Download PDF
Article Alerts
Email Article
Citation Tools
Add to Selected Citations

Trends in Hospital Admission for Diabetic Ketoacidosis in Adults With Type 1 and Type 2 Diabetes in England, 1998–2013: A Retrospective Cohort Study
Victor W. Zhong, Juhaeri Juhaeri, Elizabeth J. Mayer-Davis
Diabetes Care Sep 2018, 41 (9) 1870-1877; DOI: 10.2337/dc17-1583
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo

Jump to section